Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2020

Open Access 01-12-2020 | Gallbladder Cancer | Research

Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma

Authors: Sung Woo Ahn, Ae-Ri Ahn, Sang Hoon Ha, Usama Khamis Hussein, Jae Do Yang, Kyoung Min Kim, Ho Sung Park, See-Hyoung Park, Hee Chul Yu, Kyu Yun Jang

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Recently, FAM83H was reported to have roles in cancer progression in conjunction with oncogenic molecules such as MYC and b-catenin. Moreover, the data from the public database indicates a molecular relationship between FAM83H and zinc finger proteins, especially between FAM83H and ZNF16. However, studies on FAM83H and ZNF16 in gallbladder cancer have been limited.

Methods

This study investigated the expression of FAM83H and ZNF16 in 105 gallbladder carcinomas.

Results

In human gallbladder carcinomas, immunohistochemical expression of FAM83H was significantly associated with ZNF16 expression. In univariate analysis, nuclear and cytoplasmic expression of FAM83H or ZNF16 were significantly associated with shorter survival of gallbladder carcinoma patients. Multivariate analysis revealed the nuclear expression of FAM83H as an independent indicator of poor prognosis of overall survival (p = 0.005) and relapse-free survival (p = 0.005) of gallbladder carcinoma patients. Moreover, co-expression patterns of nuclear FAM83H and ZNF16 were also independent indicators of shorter survival of gallbladder carcinoma patients (overall survival; p <  0.001, relapse-free survival; p <  0.001).

Conclusions

This study suggests FAM83H and ZNF16 are associated with the progression of gallbladder carcinoma, and the expressions of FAM83H and ZNF16 might be novel prognostic indicators of gallbladder carcinoma patients.
Literature
1.
Kim JW, Lee SK, Lee ZH, Park JC, Lee KE, Lee MH, Park JT, Seo BM, Hu JC, Simmer JP. FAM83H mutations in families with autosomal-dominant hypocalcified amelogenesis imperfecta. Am J Hum Genet. 2008;82:489–94.CrossRef
2.
Lee SK, Hu JC, Bartlett JD, Lee KE, Lin BP, Simmer JP, Kim JW. Mutational spectrum of FAM83H: the C-terminal portion is required for tooth enamel calcification. Hum Mutat. 2008;29:E95–9.CrossRef
3.
Kuga T, Kume H, Kawasaki N, Sato M, Adachi J, Shiromizu T, Hoshino I, Nishimori T, Matsubara H, Tomonaga T. A novel mechanism of keratin cytoskeleton organization through casein kinase Ialpha and FAM83H in colorectal cancer. J Cell Sci. 2013;126:4721–31.CrossRef
4.
Kuga T, Sasaki M, Mikami T, Miake Y, Adachi J, Shimizu M, Saito Y, Koura M, Takeda Y, Matsuda J, Tomonaga T, Nakayama Y. FAM83H and casein kinase I regulate the organization of the keratin cytoskeleton and formation of desmosomes. Sci Rep. 2016;6:26557.CrossRef
5.
Kim KM, Park SH, Bae JS, Noh SJ, Tao GZ, Kim JR, Kwon KS, Park HS, Park BH, Lee H, Chung MJ, Moon WS, Sylvester KG, Jang KY. FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC. Sci Rep. 2017;7:3274.CrossRef
6.
Kim KM, Hussein UK, Park SH, Kang MA, Moon YJ, Zhang Z, Song Y, Park HS, Bae JS, Park BH, Ha SH, Moon WS, Kim JR, Jang KY. FAM83H is involved in stabilization of beta-catenin and progression of osteosarcomas. J Exp Clin Cancer Res. 2019;38:267.CrossRef
7.
Snijders AM, Lee SY, Hang B, Hao W, Bissell MJ, Mao JH. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach. Mol Oncol. 2017;11:167–79.CrossRef
8.
Kim KM, Hussein UK, Bae JS, Park SH, Kwon KS, Ha SH, Park HS, Lee H, Chung MJ, Moon WS, Kang MJ, Jang KY. The expression patterns of FAM83H and PANX2 are associated with shorter survival of clear cell renal cell carcinoma patients. Front Oncol. 2019;9:14.CrossRef
9.
Jen J, Wang YC. Zinc finger proteins in cancer progression. J Biomed Sci. 2016;23:53.CrossRef
10.
Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M, Melino G, Raschella G. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.CrossRef
11.
Peng H, Du ZW, Zhang JW. Identification and characterization of a novel zinc finger protein (HZF1) gene and its function in erythroid and megakaryocytic differentiation of K562 cells. Leukemia. 2006;20:1109–16.CrossRef
12.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.CrossRef
13.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.CrossRef
14.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.CrossRef
15.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
16.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
17.
Board WCoTE. Digestive system tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
18.
Triner D, Castillo C, Hakim JB, Xue X, Greenson JK, Nunez G, Chen GY, Colacino JA, Shah YM. Myc-associated zinc finger protein regulates the Proinflammatory response in colitis and Colon Cancer via STAT3 signaling. Mol Cell Biol. 2018;38.
19.
Amin MB, American Joint Committee on Cancer., American Cancer Society.: AJCC cancer staging manual, Eight edition / editor-in-chief, Mahul B. Amin, MD, FCAP ; editors, Stephen B. Edge, MD, FACS and 16 others ; Donna M. Gress, RHIT, CTR - Technical editor ; Laura R. Meyer, CAPM - Managing editor. edn. Chicago: American Joint Committee on Cancer, Springer; 2017.
20.
Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed
21.
Kang MA, Lee J, Ha SH, Lee CM, Kim KM, Jang KY, Park SH. Interleukin4Ralpha (IL4Ralpha) and IL13Ralpha1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways. Cancers (Basel). 2019;11:1394.
22.
Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, Hussein UK, Zhang Z, Park HS, Park BH, Moon WS, Kim JR, Jang KY. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. J Exp Clin Cancer Res. 2018;37:107.CrossRef
23.
Ding Y, Estrella MR, Hu YY, Chan HL, Zhang HD, Kim JW, Simmer JP, Hu JC. Fam83h is associated with intracellular vesicles and ADHCAI. J Dent Res. 2009;88:991–6.CrossRef
24.
Kuga T, Kume H, Adachi J, Kawasaki N, Shimizu M, Hoshino I, Matsubara H, Saito Y, Nakayama Y, Tomonaga T. Casein kinase 1 is recruited to nuclear speckles by FAM83H and SON. Sci Rep. 2016;6:34472.CrossRef
25.
Deng MJ, Li XB, Peng H, Zhang JW. Identification of the trans-activation domain and the nuclear location signals of human zinc finger protein HZF1 (ZNF16). Mol Biotechnol. 2010;44:83–9.CrossRef
26.
Li XB, Chen J, Deng MJ, Wang F, Du ZW, Zhang JW. Zinc finger protein HZF1 promotes K562 cell proliferation by interacting with and inhibiting INCA1. Mol Med Rep. 2011;4:1131–7.PubMed
27.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Ponten F. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.CrossRef
28.
Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50–60.CrossRef
29.
Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduction Targeted Therapy. 2018;3:1–7.CrossRef
30.
Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E. EMT: a mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:29–39.CrossRef
31.
Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10:6623–40.CrossRef
32.
Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48.CrossRef
33.
Oei AL, Vriend LE, van Leeuwen CM, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJ, Crezee J, Kanaar R, Kok HP, Krawczyk PM, Franken NA. Sensitizing thermochemotherapy with a PARP1-inhibitor. Oncotarget. 2017;8:16303–12.CrossRef
34.
Avila-Arroyo S, Nunez GS, Garcia-Fernandez LF, Galmarini CM. Synergistic effect of Trabectedin and Olaparib combination regimen in breast Cancer cell lines. J Breast Cancer. 2015;18:329–38.CrossRef
35.
Carey LA, Sharpless NE. PARP and cancer--if it's broke, don’t fix it. N Engl J Med. 2011;364:277–9.CrossRef
Metadata
Title
Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma
Authors
Sung Woo Ahn
Ae-Ri Ahn
Sang Hoon Ha
Usama Khamis Hussein
Jae Do Yang
Kyoung Min Kim
Ho Sung Park
See-Hyoung Park
Hee Chul Yu
Kyu Yun Jang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-00985-1

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue

Research

HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population

Case Report

Low grade malignant eccrine spiradenoma of the vulva: case report, review of the literature and discussion about the role of p53 and HPV

Research

Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm

Research

Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions

Case Report

Deadly combination of E-cigarettes has become a popular-lnduced lung injury and Influenza: case report

Case Report

P63-negative pulmonary NUT carcinoma arising in the elderly: a case report